ipilimumab
BMS's Opdivo-Yervoy Combo Approved in Europe for First-Line Treatment of Certain Colorectal Cancers
The drug combo is the first dual checkpoint inhibitor therapy approved in Europe for first-line metastatic MSI-H or dMMR colorectal cancer.
EMA's CHMP Recommends Approval for First-Line Opdivo-Yervoy in Certain Colorectal Cancers
Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.
Researchers at the ESMO Congress presented data showing better responses on dual-checkpoint blockade in the biomarker-defined subset relative to all-comers.
Gritstone Bio Eyes Pivotal Trial for Personalized Cancer Vaccine as Early ctDNA Endpoint Disappoints
Premium
Granite didn't improve molecular response, but the firm is talking up what it sees as other positive signs for its bespoke vaccine in MSS colorectal cancer.
UK, Australian Researchers ID Tumor-Agnostic Microbiome Signature to Predict Opdivo-Yervoy Response
Premium
Researchers uncovered 22 bacteria that could predict which patients do and do not respond to combination checkpoint inhibitors across diverse cancer types.